Orion and Propeller Health bring digital medicines to asthma and COPD patients

Companies come together to link inhalers and digital medical platform

Orion Corporation and Propeller Health have announced a partnership to connect the Easyhaler line of inhalers for asthma and COPD to Propeller's digital medicine platform.

The partnership will expand Propeller's presence in Europe, where Orion serves patients across several countries.

Propeller's platform currently covers more than 90% of inhaled medicines for asthma and COPD on the market.

Orion's existing line of Easyhaler products will connect to Propeller's digital medicine platform via a small, custom-built sensor.

This partnership with Orion is another significant step toward reducing the burden of chronic respiratory disease for people around the world

The sensor, which is being developed collaboratively under this agreement, attaches to the inhaler and pairs with a mobile app.

Propeller automatically tracks medication use and provides personal feedback and insights that help individuals and their doctors manage and reduce symptoms.

Development of the sensor will begin in 2019, with clinical trials, possible real-world evidence projects and a broader commercial rollout to follow.

"By connecting Easyhaler to Propeller's digital platform, we are giving our patients and their providers a new ability to improve the user experience of Easyhaler products and help patients better adhere to the treatments," said Satu Ahomäki, Orion's senior vice president of commercial operations.

People and their physicians are eager for medicines that put digital to work to improve their treatments and quality of life

"We are thrilled to take this step to reduce the burden of asthma and COPD via a digital companion to our medicine."

"People and their physicians are eager for medicines that put digital to work to improve their treatments and quality of life," adds David Van Sickle, co-founder and chief executive of Propeller Health.

"This partnership with Orion is another significant step toward reducing the burden of chronic respiratory disease for people around the world."

Companies